NCT03368300 (CAP) is a NA clinical trial of Clinical and biological exam in Atypical Parkinsonism, sponsored by Centre Hospitalier Universitaire de la Guadeloupe.

Who is sponsoring NCT03368300?

NCT03368300 is sponsored by Centre Hospitalier Universitaire de la Guadeloupe.

What drugs are being tested in NCT03368300?

Interventions in NCT03368300: Clinical and biological exam.

What condition does NCT03368300 study?

NCT03368300 studies Atypical Parkinsonism.

Is NCT03368300 still recruiting?

NCT03368300 is currently status unknown. Last updated 11 December 2017.

Last reviewed 2017-12-11 · How we verify

NCT03368300: CAP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans

Status unknown NA Last updated 11 December 2017

What this trial tests

NA trial testing Clinical and biological exam in Atypical Parkinsonism in 550 participants. Status unknown.

Timeline

3 August 2012

Primary endpoint
3 August 2018

3 August 2023

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de la Guadeloupe
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	550
Start date	3 August 2012
Primary completion	3 August 2018
Estimated completion	3 August 2023
Sites	2 locations across French Guiana, Martinique

Drugs / interventions tested

Clinical and biological exam

Conditions studied

Atypical Parkinsonism — all drugs for Atypical Parkinsonism →

Sponsor

Centre Hospitalier Universitaire de la Guadeloupe

Who can join

19 and older, any sex, with Atypical Parkinsonism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this study is to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism.
Cleret de Langavant L, Roze E, Petit A, Tressières B, et al · · 2022 · cited 11× · PMID 36210778 · DOI 10.1002/mds.29222
The Clinical Effect of Annonaceae Fruit Consumption on Caribbean Parkinson's Disease Severity.
Ribeyron L, Petit A, Edragas R, Belson S, et al · · 2026 · PMID 42192274 · DOI 10.1155/bn/8897550

Verify or expand the search:

Other recruiting trials for Atypical Parkinsonism

Currently open trials in the same condition.

NCT06596746 — Neurodegenerative Diseases Progression Markers (MARKERS-NDD) · recruiting
NCT06122662 — AMX0035 and Progressive Supranuclear Palsy · Phase 2, PHASE3 · active not recruiting
NCT06528964 — Proteinopathies Expression in Skin of Neurodegenerative Disorders · recruiting
NCT06501469 — Biomarkers in Parkinsonian Syndromes · recruiting
NCT03924414 — Trial of Parkinson's And Zoledronic Acid · Phase 4 · active not recruiting

Other Centre Hospitalier Universitaire de la Guadeloupe trials

Trials by the same sponsor.

NCT07266376 — Validation of a VOICE MAnagement Program in Schizophrenia VVoice MAPS · NA · not yet recruiting
NCT07292454 — Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe · not yet recruiting
NCT07265986 — Comparison Between a Robotic Tele-echo-cardiography Technique and a Standard Echocardiography in the Management of Heart · NA · recruiting
NCT07330830 — Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (A · recruiting
NCT07233447 — Prevalence of H. Pylori in Stomach Cancers in the West Indies · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03368300 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de la Guadeloupe
Last refreshed: 11 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03368300.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing